etoposide has been researched along with amifostine anhydrous in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 16 (69.57) | 29.6817 |
| 2010's | 4 (17.39) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Battaglia, A; Bonanno, G; Fattorossi, A; Leone, G; Mancuso, S; Menichella, G; Panici, PB; Perillo, A; Pierelli, L; Scambia, G | 1 |
| Bodalski, J; Bolanowski, W; Nowak, K; Stolarska, M; Zalewska-Szewczyk, B | 1 |
| Brown, JM; Gurney, EM; Hepburn, PM; Johnson, PW; Muers, MF; Napp, VV; Peake, MD; Poulter, KM | 1 |
| Ayash, LJ; Cronin, S; Raith, C; Ratanatharathorn, V; Uberti, JP | 1 |
| Berthold, F; Fichtner, I; Fulda, S; Hero, B | 1 |
| Baruchel, S; Fouladi, M; Gammon, J; Grant, R; Greenberg, ML; Klein, J; Koren, G; Stempak, D | 1 |
| Allen, P; Cox, JD; Fossella, FV; Glisson, B; Herbst, R; Hong, WK; Kaplan, B; Kelly, JF; Khuri, F; Komaki, R; Kurie, J; Lee, JS; Liao, Z; Milas, L; Papadimitrakopoulou, V; Pisters, K; Ro, J; Stevens, CW; Thames, HD; Zinner, R | 1 |
| Forster, KM; Gopal, R; Kelly, JF; Komaki, R; Liao, Z; Starkschall, G; Stevens, C; Tucker, SL | 1 |
| Allen, PK; Blumenschein, GR; Cox, JD; Fossella, FV; Garza, VP; Glisson, BS; Herbst, RS; Kaplan, B; Kies, MS; Komaki, R; Kurie, J; Lee, HK; Lee, JS; Liao, Z; Lu, C; Milas, L; Mooring, D; Papadimitrakopoulou, VA; Pisters, KM; Stevens, CW; Tucker, SL; Zinner, RG | 1 |
| Chen, BA; Chen, J; Cheng, J; Cheng, X; Ding, JH; Fu, Q; Gao, C; Gao, F; Huang, CY; Li, CP; Sun, GY; Wang, J; Zhou, M | 1 |
| Chen, BA; Ding, JH; Gao, C; Li, CP; Zhou, M | 1 |
| Abboud, CN; Bernstein, SH; Chapman, M; Friedberg, JW; Ifthikharuddin, JJ; Johnson, V; Lancet, JE; Liesveld, JL; Phillips, GL; Spreng, E; Vesole, DH | 1 |
| Billmire, DF; Chang, KW; Davis, MM; Frazier, AL; Giller, R; Lauer, SJ; London, WB; Malogolowkin, M; Marina, N; Olson, TA; Perlman, EJ; Rescorla, F; Womer, RB | 1 |
| Bot, BM; Garces, YI; Jett, JR; Kozelsky, TF; Mandrekar, SJ; Martens, JM; Moore, DF; Okuno, SH; Schild, SE; Soori, GS; Wender, DB | 1 |
| Chen, ZC; Li, QB; Tang, XQ; Wang, HX; You, Y; Zhao, ZG; Zou, P | 1 |
| Cheerva, AC; Gross, TG; Kadota, RP; Levine, JE; Ozkaynak, MF; Richards, MK; Rozans, MK; Sahdev, I; Shaw, PJ | 1 |
| Albain, K; Bae, K; Curran, WJ; Gore, EM; Komaki, R; Machtay, M; Movsas, B; Paulus, R; Sause, WT | 1 |
| Abboud, CN; Becker, MW; Bernstein, SH; Constine, LS; Friedberg, JW; Ifthikharuddin, JJ; Liesveld, JL; Loughner, JE; Milner, LA; Phillips, GL; Vesole, DH | 1 |
| Calandrelli, M; Capelli, D; Chiarucci, M; Gini, G; Inglese, E; Leoni, P; Mancini, G; Mancini, S; Montanari, M; Offidani, M; Olivieri, A; Poloni, A; Raggetti, G; Scortechini, I | 1 |
| Boutros, SW; Holden, S; Krenik, D; Raber, J; Unni, VK | 1 |
1 review(s) available for etoposide and amifostine anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 trial(s) available for etoposide and amifostine anhydrous
| Article | Year |
|---|---|
A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia | 2001 |
Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Topics: Adolescent; Amifostine; Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Cell Division; Child; Child, Preschool; Cisplatin; Cross-Over Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Etoposide; Humans; Ifosfamide; Mercaptoethylamines; Mice; Mice, Nude; Neuroblastoma; Neutropenia; Prodrugs; Safety; Thrombocytopenia; Treatment Failure; Tumor Cells, Cultured; Vincristine; Vomiting; Xenograft Model Antitumor Assays | 2001 |
Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Male; Mercaptoethylamines; Neoplasms; Treatment Failure | 2001 |
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Injuries; Radiation Pneumonitis; Radiation-Protective Agents | 2002 |
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Confidence Intervals; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Pneumonitis; Radiation-Protective Agents; Radiotherapy Dosage; Survival Analysis; Treatment Outcome | 2004 |
Phase I study for poor-prognosis lymphoma: augmentation of the "BEAM" regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation--a preliminary report.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Cytoprotection; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Middle Aged; Radiation-Protective Agents; Transplantation, Autologous | 2004 |
Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality Control; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Dosage; Topotecan | 2007 |
A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Etoposide; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hypocalcemia; Kidney Neoplasms; Melphalan; Neoplasms; Neuroblastoma; Pilot Projects; Recurrence; Risk Factors; Sarcoma; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Wilms Tumor | 2008 |
Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Radiotherapy Dosage; Relative Biological Effectiveness; Retrospective Studies; Survival Analysis; Treatment Failure; Vinblastine | 2012 |
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carmustine; Combined Modality Therapy; Cytarabine; Cytoprotection; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lymphoma; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Mucositis; Pancytopenia; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2011 |
12 other study(ies) available for etoposide and amifostine anhydrous
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.
Topics: Amifostine; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Cell Cycle; Cell Division; Cells, Cultured; Docetaxel; Doxorubicin; Etoposide; Hematopoietic Stem Cells; Humans; Leukocytes, Mononuclear; Paclitaxel; Taxoids; Time Factors | 1998 |
[Cytoprotective effect of amifostine in children during induction therapy according to BFM-83: report on cases].
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Retrospective Studies | 1998 |
Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Etoposide; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Kidney Diseases; Male; Testicular Neoplasms; Transplantation Conditioning | 2000 |
The relationship between local dose and loss of function for irradiated lung.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Radiation; Etoposide; Female; Humans; Imaging, Three-Dimensional; Lung; Lung Neoplasms; Male; Middle Aged; Pulmonary Diffusing Capacity; Radiation Injuries; Radiation-Protective Agents; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Respiratory Function Tests; Retrospective Studies; Tomography, X-Ray Computed | 2003 |
[Effect of S-2-(3-aminopropylamino) ethyl phosphorothioic acid on apoptosis and proliferation inhibition of HL-60 cell line].
Topics: Amifostine; Apoptosis; Cell Cycle; Cell Proliferation; Drug Synergism; Etoposide; HL-60 Cells; Humans | 2004 |
[Protective effects of amifostine on hematopoietic stem/progenitor cells against chemotherapeutic damage].
Topics: Amifostine; Antineoplastic Agents; Apoptosis; Cell Survival; Cells, Cultured; Etoposide; Flow Cytometry; Hematopoietic Stem Cells; HL-60 Cells; Humans; Leukocytes, Mononuclear; Protective Agents | 2004 |
Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study.
Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Cisplatin; Etoposide; Female; Hearing Disorders; Humans; Infant; Male; Neoplasms, Germ Cell and Embryonal; Pilot Projects; Radiation-Protective Agents | 2005 |
[Role of amifostine against the effect of etoposide on non-Hodgkin lymphoma bone marrow derived mesenchymal stem cells: an in vitro experiment].
Topics: Adult; Amifostine; Antigens, CD; Apoptosis; Bone Marrow Cells; Cell Proliferation; Cell Separation; Etoposide; Flow Cytometry; HLA-DR Antigens; Humans; Immunophenotyping; Lymphoma, Non-Hodgkin; Mesenchymal Stem Cells; Middle Aged; Time Factors | 2007 |
Conditioning regimen with BCNU, etoposide, cytarabine and melphalan plus amifostine for outpatient autologous stem cell transplant: feasibility and outcome in 97 patients with lymphoma.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Melphalan; Outpatients; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2014 |
Common cancer treatments targeting DNA double strand breaks affect long-term memory and relate to immediate early gene expression in a sex-dependent manner.
Topics: Amifostine; Animals; DNA; DNA Breaks, Double-Stranded; Etoposide; Female; Genes, Immediate-Early; Male; Memory, Long-Term; Mice; Neoplasms; Pharmaceutical Preparations | 2022 |